by Plus Therapeutics | Jun 16, 2025 | GBM
We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...
by Plus Therapeutics | Jun 16, 2025 | GBM
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
by Plus Therapeutics | Jun 12, 2025 | Uncategorized
At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D.,...
by Plus Therapeutics | Jun 10, 2025 | GBM
At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal...
by Plus Therapeutics | Jun 10, 2025 | GBM
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...
Recent Comments